Protagenic Therapeutics receives Nasdaq delisting notice; trading to move to OTC Jan 5, 2026

Protagenic Therapeutics, Inc.new

Nasdaq determined to delist PTIX and PTIXW due to failure to meet minimum stockholders' equity (Rule 5550(b)(1)) and timely filing (Rule 5250(c)(1)).
Trading on Nasdaq will cease at close of Jan 2, 2026; OTC trading expected to start Jan 5, 2026.
Company has withdrawn its hearing request, making delisting final.
Company intends to evaluate steps to regain compliance and seek relisting on Nasdaq.

item 3.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.